Drug & intervention

everolimus

RxCUI 141704

Clinical trials132
Recruiting10
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Everolimus

Everolimus, sold under the brand name Afinitor among others, is a medication used as an immunosuppressant to prevent rejection of organ transplants and as a targeted therapy in the treatment of renal cell cancer and other tumours. This compound also has a use in cardiovascular drug-eluting stent technologies to inhibit restenosis. It is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR). It is marketed by Novartis under the trade names Zortress (US) and Certican (European Union and other countries) in transplantation medicine, and as Afinitor (general tumours) and Votubia (tumours as a result of Tuberous Sclerosis Complex (TSC)) in oncology. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.

Read on Wikipedia ↗ Wikidata Q421052 ↗
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.NCT07062965 · 2025-08-05
RECRUITING
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.NCT06382948 · 2024-12-05
RECRUITING
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 InhibitorNCT05933395 · 2024-09-23
RECRUITING
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.NCT05918302 · 2023-10-27
RECRUITING
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast CancerNCT05983107 · 2023-07-20
RECRUITING
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine TumorsNCT04665739 · 2023-02-03
RECRUITING
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerNCT05573126 · 2023-01-11
RECRUITING
SNF Platform Study of HR+/ HER2-advanced Breast CancerNCT05594095 · 2022-12-30
RECRUITING
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerNCT04802759 · 2021-06-22
RECRUITING
Safety and Durability of Sirolimus for Treatment of LAMNCT02432560 · 2015-03-01
RECRUITING
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)NCT06428396 · 2024-11-27
ACTIVE_NOT_RECRUITING
Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular SubtypingNCT06561022 · 2024-08-21
UNKNOWN
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of TreatmentNCT06105632 · 2024-01-09
ACTIVE_NOT_RECRUITING
Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) SubtypeNCT05954442 · 2023-09-13
UNKNOWN
A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)NCT05252585 · 2023-05-01
ACTIVE_NOT_RECRUITING
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerNCT05563220 · 2023-01-24
ACTIVE_NOT_RECRUITING
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerNCT05508906 · 2022-08-31
ACTIVE_NOT_RECRUITING
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)NCT05306340 · 2022-08-03
ACTIVE_NOT_RECRUITING
Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast CancerNCT05293964 · 2022-05-18
ACTIVE_NOT_RECRUITING
Precise Therapy for Refractory HER2 Positive Advanced Breast CancerNCT05429684 · 2021-01-01
UNKNOWN
Topical Everolimus in Patients With Tuberous Sclerosis ComplexNCT02860494 · 2020-12-01
WITHDRAWN
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyNCT04591431 · 2020-10-07
UNKNOWN
Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerNCT04355858 · 2020-05-01
UNKNOWN
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialNCT03878524 · 2020-04-01
TERMINATED
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerNCT04188548 · 2019-12-10
ACTIVE_NOT_RECRUITING
Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway DeficiencyNCT03580239 · 2019-01-01
UNKNOWN
The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has SpreadNCT03659136 · 2018-11-28
COMPLETED
Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.NCT03525834 · 2018-11-09
COMPLETED
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE ScoreNCT03386539 · 2018-01-29
COMPLETED
Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast CancerNCT03284957 · 2017-09-20
TERMINATED
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase InhibitorNCT03312738 · 2017-09-15
COMPLETED
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentNCT02962414 · 2017-08-23
ACTIVE_NOT_RECRUITING
Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and BreastNCT03154281 · 2017-07-26
COMPLETED
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast CancerNCT03032406 · 2017-01-23
ACTIVE_NOT_RECRUITING
A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatNCT02890069 · 2016-10-14
COMPLETED
Palbociclib With Everolimus + Exemestane In BCNCT02871791 · 2016-08-24
COMPLETED
Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung CancerNCT02321501 · 2016-06-22
ACTIVE_NOT_RECRUITING
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.NCT02732119 · 2016-06-14
COMPLETED
A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast CancerNCT02742051 · 2016-06-01
COMPLETED
Impact of Everolimus on HIV Persistence Post Kidney or Liver TransplantNCT02429869 · 2016-02-24
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.